Cancer: Drugs

(asked on 10th December 2014) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, how many treatments on the Cancer Drugs Fund list scored points for addressing unmet need when appraised by the decision making panel.


Answered by
George Freeman Portrait
George Freeman
This question was answered on 15th December 2014

Since April 2013, the following three drugs have been reviewed by NHS England’s Cancer Drugs Fund panel and added to the Cancer Drugs Fund list after scoring points for unmet need.

- lenalidomide (Revlimid) for transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q or an isolated deletion 5q plus one other cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

- ponatinib (Iclusig) for Chronic-phase, accelerated-phase, or blast-phase chronic myeloid leukaemia (CML) with the T315I mutation or Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) with the T315I mutation.

- vismodegib (Erivedge) for patients with advanced basal cell carcinoma (aBCC) who are no longer appropriate for any other treatment options.

All decisions made by NHS England’s Cancer Drugs Fund panel including the detail of agreed scores for each drug reviewed by the panel since its formation in April 2013, are published on its website at:

www.england.nhs.uk/ourwork/pe/cdf/

Reticulating Splines